AKT1 and primary central nervous system lymphoma: In summary, the study may enable the development of practical molecular targeted therapies, such as RTKs including EGF receptor family upstream at RAS-MAP-kinase and FAS death receptor merged into the PI3K-PTEN-AKT proapoptotic pathway based on the diagnosis and prognosis in PCNSL.